This German Biotech's Novel Approach Could Redefine Heart Disease Treatment

Jan de Vries · 2026-08-28

You know how sometimes a piece of news just makes you stop and think about the bigger picture? That's what this story about Revier Therapeutics, a new biotech player out of Heidelberg, Germany, does. They've just launched and secured a significant $6.5 million seed round to chase a bold goal: developing next-generation therapies for cardiometabolic diseases like heart failure. It's a huge market need. But what makes this startup different isn't just the funding—it's the science. They're going after a target that's been notoriously tricky, aiming to deliver treatments that actually modify the course of the disease, not just manage symptoms. ### The Funding and the Vision Behind It The $6.5 million seed round was spearheaded by the KHAN Technology Transfer Fund II. They brought along some notable co-investors, including High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors organized through Revier Invest Heidelberg. That's a strong vote of confidence for a brand-new company. So, what's the vision spending all this capital on? Prof. Eva van Rooij, the CEO and co-founder, puts it plainly. She says that despite real progress, millions of patients with specific heart conditions still don't have great targeted options. The next wave of medicine, she argues, has to get at the root biological causes to create lasting change. Their mission is to turn the promise of a specific scientific mechanism—class IIa HDAC inhibition—into real therapies for patients. ### A New Take on an Old Target Here’s where it gets technical, but stick with me. HDACs are enzymes involved in many serious diseases. Earlier drugs that blocked them were a bit like using a sledgehammer—they hit too many targets and caused nasty side effects. Revier's approach is more like a precision scalpel. They claim to have developed the first therapy designed to selectively target just one class of these enzymes (class IIa HDACs) for cardiometabolic disease. - **The Goal:** Their orally available small molecules aim to block only the disease-causing activity. - **The Benefit:** This should, in theory, preserve healthy function and avoid the problems of older, broader inhibitors. Prof. Johannes Backs, the scientific founder, explains that this selective targeting is key to being both effective and safe, a combination that's been elusive. ### What the Investors Are Saying Michael Hamacher from KHAN Technology Transfer Fund II didn't hold back on the potential. He called Revier's strategy a way to "unlock the therapeutic promise of HDAC biology" while sidestepping past limitations. He highlighted the team's deep expertise as a major factor in their belief that the company can reshape patient care for heart failure and related disorders. ### The Road Ahead With the fresh capital in hand, Revier's plans are concrete. The money will fuel their preclinical pipeline, specifically advancing two lead programs: 1. A treatment for heart failure with preserved ejection fraction (HFpEF). 2. A second program targeting atherosclerotic cardiovascular disease (ASCVD). Beyond the lab work, they're building out their full operational, scientific, and clinical teams. It's the classic startup journey, from bold idea to tangible development, now fully funded and underway. For professionals watching the European biotech scene, this is one to keep an eye on—a blend of novel science, experienced leadership, and a clear path to addressing a massive unmet medical need.